Helicobacter pylori infection diagnostic test

	Helicobacter pylori infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology Gastritis Peptic ulcer disease Gastric adenocarcinoma MALT lymphoma
Causes
Differentiating Helicobacter pylori infection from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Guideline Recommendation ACG guidelines ESPGHAN and NASPGHAN guidelines
History and Symptoms
Physical Examination
Diagnostic tests Endoscopic tests Nonendoscopic tests
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Helicobacter pylori infection diagnostic test On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Helicobacter pylori infection diagnostic test All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Helicobacter pylori infection diagnostic test
CDC on Helicobacter pylori infection diagnostic test
Helicobacter pylori infection diagnostic test in the news
Blogs on Helicobacter pylori infection diagnostic test
Directions to Hospitals Treating Helicobacter pylori infection
Risk calculators and risk factors for Helicobacter pylori infection diagnostic test

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yamuna Kondapally, M.B.B.S [2]

Overview

Antibody testing is inexpensive and widely available but poor PPV in populations with a low prevalence of H. pylori infection limits its usefulness in clinical practice.
The UBTs and fecal antigen tests provide reliable means of identifying active H. pylori infection before antibiotic therapy.
The UBT is the most reliable nonendoscopic test to document eradication of H. pylori infection.
The monclonal fecal antigen test provides another nonendoscopic means of establishing H. pylori cure after antibiotic treatment.
Testing to prove H. pylori eradication appears to be most accurate if performed at least 4 wk after the completion of antibiotic therapy.

The nonendoscopic diagnostic testing methods for H.pylori include:

Antibody testing depends on the detection of H.pylori specific IgG antibodies in serum, whole blood, or urine.^[1]
The IgG antibodies typically become detected 21 days after infection and can remain present long after eradication.
Antibodies are detected using enzyme-linked immunosorbent assay (ELISA) and latex agglutination techniques.

The urea labeled with either the nonradioactive isotope 13C or the radioactive isotope 14C is ingested.
The H.pylori urease converts labeled urea to CO2, which can be quantitated in expired breath.

13C labeled urea is preferred in children and pregnant females.
Urea breath test has 95% sensitivity and specificity.
This test is an accurate means of post-treatment testing.
As this test mainly depends on urease activity of H.pylori, the sensitivity of test is decreased by medications such as bismuth containing products, PPIs and antibiotics as they reduce organism density or urease activity. It is recommended to with hold PPIs for 7-14 days prior to test, and bismuth and antibiotics are withheld for at least 28days.
Antacids do not affect the efficacy of the test.

The fecal antigen test (FAT) is an enzyme immunoassay which identifies H.pylori antigen with the use of polyclonal anti-H.pylori antibody.
Monoclonal antibodies can also be used to identify fecal H.pylori antigens.
Both tests are used to screen for infection and post treatment testing.
Fecal antigen test is approved by U.S Food and Drug Administration as an alternative means of establishing H.pylori cure to urea breath test.
The polyclonal test has excellent sensitivity, specificity, and predictive values before treatment but less satisfactory after the treatment.
This test may be effective in confirming eradication of H.pylori infection as early as 14 days after treatment. However, it is suggested that it should be done more than 4 wk and upto 8-12 wk after h.pylori treatment.
The sensitivity of test is affected by the use of PPIs, bismuth compounds, and antibiotics. The specificity is affected by the bleeding peptic ulcer disease.

Nonendoscopic testing	Advantages	Disadvantages
1. Antibody testing (quantitative and qualitative)	Inexpensive, widely available, very good NPV	PPV dependent upon background H. pyloriprevalence. Not recommended after H. pyloritherapy
*2. Urea breath tests (13C and 14C)	Identifies active H. pylori infection. Excellent PPV and NPV regardless of H. pylori prevalence. Useful before and after H. pylori therapy	Reimbursement and availability remain inconsistent
*3. Fecal antigen test	Identifies active H. pylori infection. Excellent positive and negative predictive values regardless of H. pylori prevalence. Useful before and after H. pylori therapy	Polyclonal test less well validated than the UBT in the posttreatment setting. Monoclonal test appears reliable before and after antibiotic therapy. Unpleasantness associated with collecting stool